influenza virus vaccine quadrivalent + MAS-1

influenza virus vaccine quadrivalent + MAS-1 is an investigational adjuvanted vaccine candidate developed by **PDS Biotechnology**. It combines a standard quadrivalent influenza vaccine (QIV)—which typically targets two Influenza A strains (H1N1 and H3N2) and two Influenza B strains (Victoria and Yamagata lineages)—with the proprietary **MAS-1** adjuvant system. MAS-1 is a lipid-based adjuvant that acts as a **Toll-like receptor 4 (TLR4) agonist**, designed to stimulate a robust and balanced immune response involving both neutralizing antibodies and T-cell activation. The primary goal of this combination is to enhance the immunogenicity and breadth of protection of seasonal influenza vaccines, particularly in populations with weakened immune responses such as the elderly, and to provide better defense against antigenically drifted viral strains. The MAS-1 platform is also being utilized in the development of universal influenza vaccines (e.g., PDS0204) that incorporate conserved viral antigens.

Other names

MAS-1 adjuvanted quadrivalent influenza vaccineMAS1 adjuvanted quadrivalent influenza vaccineMAS 1 adjuvanted quadrivalent influenza vaccinePDS0204PDS-0204PDS 0204